Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

815 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia.
Ovcharenko D, Stölzel F, Poitz D, Fierro F, Schaich M, Neubauer A, Kelnar K, Davison T, Müller-Tidow C, Thiede C, Bornhäuser M, Ehninger G, Brown D, Illmer T. Ovcharenko D, et al. Among authors: ehninger g. Exp Hematol. 2011 Oct;39(10):1030-1042.e7. doi: 10.1016/j.exphem.2011.07.008. Epub 2011 Jul 22. Exp Hematol. 2011. PMID: 21784052 Free article.
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.
Thiede C, Steudel C, Mohr B, Schaich M, Schäkel U, Platzbecker U, Wermke M, Bornhäuser M, Ritter M, Neubauer A, Ehninger G, Illmer T. Thiede C, et al. Among authors: ehninger g. Blood. 2002 Jun 15;99(12):4326-35. doi: 10.1182/blood.v99.12.4326. Blood. 2002. PMID: 12036858 Free article.
Successful combination of anti-CD33 antibody (gemtuzumab ozogamicin) and minimal conditioning before second allografting in recurrent acute myeloid leukaemia.
Hänel M, Thiede C, Helwig A, Prange-Krex G, Babatz J, Haack M, Kroschinsky F, Fetscher S, Ehninger G, Bornhäuser M. Hänel M, et al. Among authors: ehninger g. Br J Haematol. 2003 Mar;120(6):1093-4. doi: 10.1046/j.1365-2141.2003.04208_4.x. Br J Haematol. 2003. PMID: 12648086 Free article. No abstract available.
Increased myelotoxicity of idarubicin: is there a pharmacological basis? Results of a pharmacokinetic and an in vitro cytotoxicity study.
Kroschinsky F, Schleyer E, Renner U, Schimming C, Schimmelpfennig C, Bornhäuser M, Illmer T, Trümper L, Ehninger G, Schaich M. Kroschinsky F, et al. Among authors: ehninger g. Cancer Chemother Pharmacol. 2004 Jan;53(1):61-7. doi: 10.1007/s00280-003-0700-2. Epub 2003 Sep 3. Cancer Chemother Pharmacol. 2004. PMID: 12955471 Clinical Trial.
CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid.
Bornhauser M, Jenke A, Freiberg-Richter J, Radke J, Schuler US, Mohr B, Ehninger G, Schleyer E. Bornhauser M, et al. Among authors: ehninger g. Ann Hematol. 2004 Jun;83(6):401-2. doi: 10.1007/s00277-003-0829-4. Epub 2003 Dec 12. Ann Hematol. 2004. PMID: 14673623
815 results